Cargando…
Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation
BACKGROUND: Guselkumab is a drug used to treat moderate to severe plaque psoriasis. However, real-life clinical data on its off-label use are limited, especially regarding the optimal drug dosage regimen for different patient profiles. OBJECTIVE: The main objective of this real-world, single-centre,...
Autores principales: | Herranz-Pinto, Pedro, Alonso-Pacheco, Maria Luisa, Feltes-Ochoa, Rosa, Mayor-Ibarguren, Ander, Servera-Negre, Guillermo, Busto-Leis, Jose Manuel, Gonzalez-Fernández, Maria Angeles, Herrero-Ambrosio, Alicia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374766/ https://www.ncbi.nlm.nih.gov/pubmed/37402097 http://dx.doi.org/10.1007/s40261-023-01280-9 |
Ejemplares similares
-
Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2022) -
Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series
por: Mayor Ibarguren, Ander, et al.
Publicado: (2021) -
Guselkumab for plaque psoriasis
Publicado: (2019) -
Guselkumab for the treatment of psoriasis – evidence to date
por: Nogueira, Miguel, et al.
Publicado: (2019) -
Vascular Tumor on the Forehead of an HIV Patient
por: Ibarguren, Ander Mayor, et al.
Publicado: (2015)